ArticleClinicoEconomics and outcomes research : CEOR2021

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation.

Taru Hallinen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.